Suppr超能文献

慢性β受体阻滞剂对犬心脏β受体及腺苷酸环化酶活性的影响。

Effects of chronic beta-blockade on beta-receptors and adenylate cyclase activity in the canine heart.

作者信息

Becker D M, Romano F D, Scanlon P J, Jones S B, Euler D E

机构信息

Department of Medicine, Loyola University Medical Center, Maywood, Ill.

出版信息

Pharmacology. 1988;36(3):172-82. doi: 10.1159/000138381.

Abstract

To test the hypothesis that beta-receptors 'up-regulate' during chronic beta-blockade, myocardial beta-receptor density, affinity and functional sensitivity were examined in dogs before and after chronic beta-blockade. Membrane preparations from the left ventricle and right atrium were assayed for beta-receptors in 8 control dogs, and 8 dogs given oral nadolol (4 mg/kg) twice a day for 3 weeks. Beta-receptor density and affinity of membrane fractions were determined using 3H-dihydroalprenolol (0.5-20 nM), and Scatchard analysis. Beta-receptor densities after chronic beta-blockade were 419 +/- 28 (mean +/- SEM) and 436 +/- 47 fmol/mg protein in membranes from the left ventricle and right atrium respectively. These values were not significantly different from the left ventricle (412 +/- 25) or the right atrium (413 +/- 25) in control dogs. Beta-receptor affinities were 5.6 +/- 0.5 nM (left ventricle) and 8.5 +/- 1.1 nM (right atrium) after chronic beta-blockade, and not significantly different from control (6.9 +/- 0.7 nM, ventricle; 11.3 +/- 0.9 nM, atrium). Beta-receptor sensitivity was determined in membrane fractions from the left ventricle by analysis of the dose-response relationship between isoproterenol and the formation of c-AMP (pmol/min/mg protein). The concentration of isoproterenol that resulted in 50% of the maximal response was not significantly altered by chronic beta-blockade. Maximally stimulated adenylate cyclase with Gpp(NH)p or NaF was also unchanged by beta-blockade. These results suggest that in the canine heart, chronic beta-blockade does not lead to 'up-regulation' of beta-receptors nor catecholamine supersensitivity.

摘要

为验证慢性β受体阻滞剂治疗期间β受体“上调”这一假说,研究人员检测了犬在慢性β受体阻滞剂治疗前后心肌β受体密度、亲和力及功能敏感性。对8只对照犬以及8只每天口服两次纳多洛尔(4毫克/千克),持续3周的犬,测定其左心室和右心房膜制剂中的β受体。使用3H-二氢阿普洛尔(0.5 - 20纳摩尔)及Scatchard分析来测定膜组分的β受体密度和亲和力。慢性β受体阻滞剂治疗后,左心室和右心房膜中的β受体密度分别为419±28(平均值±标准误)和436±47飞摩尔/毫克蛋白。这些数值与对照犬左心室(412±25)或右心房(413±25)相比无显著差异。慢性β受体阻滞剂治疗后,β受体亲和力在左心室为5.6±0.5纳摩尔,右心房为8.5±1.1纳摩尔,与对照(心室6.9±0.7纳摩尔;心房11.3±0.9纳摩尔)相比无显著差异。通过分析异丙肾上腺素与环磷酸腺苷(c-AMP)生成(皮摩尔/分钟/毫克蛋白)之间的剂量反应关系,测定左心室膜组分中的β受体敏感性。慢性β受体阻滞剂治疗未显著改变产生最大反应50%时的异丙肾上腺素浓度。用Gpp(NH)p或NaF最大程度刺激的腺苷酸环化酶也未因β受体阻滞剂而改变。这些结果表明,在犬心脏中,慢性β受体阻滞剂治疗不会导致β受体“上调”,也不会引起儿茶酚胺超敏反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验